After a plunge, the number of permits issued for drug trials in Russia is leveling out. According to Sergey Glagolev, Deputy Head of the Ministry, the decrease in the number of permits issued for international multicenter clinical trials was compensated by the growth of local trials.
“The first challenge we faced in February 2022 was caused primarily by the drop in applications for new international multicenter clinical trials. Despite this, the situation is stabilizing – the decrease in the number of permits issued for international multicenter clinical trials was compensated by the growth of local research,” he said during a round table of the State Duma Committee on Health Protection.
Glagolev noted the interest of the Eastern countries in launching, including in cooperation with Russian manufacturers, of me too class products (drugs with similar clinical results compared to existing first-in-class drugs), which also require multicenter clinical trials.